Prosetta, BMS form multi-year antiviral drug development collaboration

Wednesday, August 1, 2012 01:56 PM

Prosetta Antiviral, a San Francisco-based biotechnology company, has formed a strategic alliance with global biopharmaceutical company Bristol-Myers Squibb (BMS) to further discover and develop select drug candidates representing new, novel classes of antiviral drugs.

Currently, Prosetta has a portfolio comprising novel chemical classes of small molecules with antiviral activity which target catalytic host protein interactions essential for the virus, but not the host. These molecules represent a new therapeutic approach for antiviral agents.

The collaboration will include a research program focused on the discovery and advancement of compounds shown to block viral capsid assembly using Prosetta’s proprietary drug discovery platform. BMS will have the right to develop and commercialize products arising from the research program.

Prosetta will receive an upfront payment and multi-year research funding. The company is also eligible to receive milestone payments and royalties based on worldwide sales of the drugs emerging from the collaboration.

Share:          
CWWeekly

July 27

AB Science warned about putting study volunteers in danger

FDA, Google unite to detect search-data adverse events

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

Integrated research partnerships build momentum
Research function provides infrastructure, leverages large pool of health systems' patients and data

'Right to Try' laws challenge clinical trial process
20 states pass, 20 more pending allowing access to study drugs without FDA and IRB approval

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs